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Abstract
An increasing number of genetic tests for cardiomyopathies are becoming available for clinical use.
This commentary will give a short overview of indications and challenges concerning genetic testing
for these conditions.
Introduction and context
Over the last decade, we have witnessed a number of
cardiomyopathies entering the genetic era. Considerable
knowledge of pathophysiology in these diseases has
originated from the discovery of mutations in genes
encoding ion channel proteins and structural cellular
proteins. Pathophysiologicalconsiderations have led to a
redefinition of cardiomyopathies [1]. There are several
cardiomyopathies for which genetic diagnostics are
available and should be considered in a clinical setting,
such as the electrical cardiomyopathies, including the
long and short QT syndrome (LQTS and SQTS), Brugada
syndrome, and catecholaminergic polymorphic ventri-
cular tachycardia (CPVT), and the cardiomyopathies
withstructuralalterations,includinghypertrophiccardio-
myopathy (HCM), dilated cardiomyopathy (DCM), and
arrhythmogenic right ventricular cardiomyopathy
(ARVC).
Genetic tests for these diseases have varying degrees of
accessibility and sensitivity. Before genotyping is
initiated, a clinical phenotype has to be present.
Genotyping may confirm the diagnosis and provide
additional risk information. Most of the inherited
cardiomyopathies are autosomal dominantly inherited.
Having a mutation carrier in the family implies that the
risk for a sister, brother, child, or parent to carry the
family mutation is 50%. Family screening targets these
family members. Genetic screening can identify indivi-
duals who may develop cardiomyopathy and has the
additional substantial benefit of assuring approximately
50% of the tested relatives of their negative mutation
status.
Recent advances
Molecular genetic studies continually demonstrate addi-
tional genes and loci associated with different cardio-
myopathies (Table 1). Consequently, more patients
receive a molecular genetic diagnosis and more family
members are involved in screening procedures.
Genotypedatahavebeenknownforalimitedtimeandin
a restricted number of populations. Therefore, genotype-
phenotype data still have to be collected to guide the
clinician in managing mutation carriers and their family
members. Indeed, there appear to be differences between
the phenotypic consequences of mutations in different
genes and also between different mutations in the same
gene [2]. An illustration of the advantage of genotyping is
to detect lamin A/C carriers among patients with
idiopathic DCM. These mutation carriers have increased
risk of conduction disorders and arrhythmic events in
addition to ventricular dilatation and heart failure [3].
Therefore, every lamin A/C mutationcarrier has to berisk-
stratifiedregardingmalignantarrhythmias.Inthissetting,
knowing the genotype allows one to focus the clinical
resources on the high-risk individuals among DCM
patients. Recent insight has raised the awareness of the
risk of malignant arrhythmias and sudden cardiac death
inindividualswhocarryamutationforacardiomyopathy
Page 1 of 3
(page number not for citation purposes)
Published: 29 June 2009
© 2009 Medicine Reports Ltd
for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License
(http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium,with structural alterations but who have not yet devel-
oped any structural changes. This is applicable for DCM
and ARVC mutation carriers, who have increased risk for
sudden cardiac death even before the development of
clinical, manifest, structural changes.
Implications for clinical practice
Patients with cardiomyopathies should be treated in
specialized centers that have access to genetic analyses
and genetic counselling. Genetic testing is indicated in
patients with LQTS and CPVT phenotypes [4]. Particu-
larly in LQTS, the genotype provides additional informa-
tion about risk for arrhythmias [5]. Concomitant use of
several drugs for other diseases (for example, erythromy-
cin) represents an additional risk factor for arrhythmias.
Genotype information is also helpful in decisions
regarding implantable cardioverter defibrillator (ICD)
therapy. In the large majority of LQT patients, beta-
blocker therapy is obligatory as the first-choice option to
reducemortalityandlife-threateningevents.InLQT2,the
arrhythmic events are usually fewer than in LQT1 but are
often severe. In both LQT1 and LQT2 patients (which
together account for about 90% of LQT patients), ICD
therapy should be considered in case of insufficient
response on beta-blocker therapy and is obligatory after
cardiac arrest. In LQT3 syndrome, beta-blocker therapy is
doubtful since arrhythmic events usually occur at rest.
ICD is the therapy of choice in LQT3 patients. Further-
more, genetic testing is important for identifying family
members who are mutation carriers and at risk of cardiac
arrhythmias. For relatives carrying an LQTS- or CPVT-
associatedmutation,prophylacticbeta-blockertreatment
should be offered after individual risk assessment.
SQTS has been described in few patients [6-8]. Genetic
testing has a potential clinical role [4]. Treatment is
limited to ICD implantation, although medical treat-
ment with quinidine may be considered [9].
In Brugada syndrome, genetic testing has a potential
clinical role [4]. Genetic testing allows the identification
of a mutation in 15-20% of patients [10]. Preventive ICD
therapy should be considered in mutation carriers with
syncope or with a malignant family history. Silent
mutationcarriers maybenefit fromprophylacticpharma-
cological treatment with quinidine [11-13]. Prospective
trials regarding quinidine treatment are in progress [14].
Genetic testing is indicated in HCM patients. About 60%
of index cases with HCM are heterozygous for mutations
in a known disease-causing gene [15]. In normotensive
HCM patients who are mutation-negative, the clinician
may consider rare diseases like amyloidosis or Fabry
disease. In clinical practice, however, HCM usually is not
diagnosed by genetic testing, but with imaging techni-
ques. In HCM mutation-positive patients, genotyping so
far has contributed only modestly to risk assessment,
although mutations in the MYH7 gene may carry some
prognostic information [4]. Family members of muta-
tion-positive HCM patients should be screened for the
family mutation as this allows a presymptomatic
diagnosis and facilitates the allocation of resources to
high-risk individuals.
DCM in association with conduction defects indicates a
higher probability of lamin A/C mutations. Genetic
screening in this subgroup of DCM patients therefore is
simple and cost-efficient [4]. Implications for family
members are considerable as mentioned above [3]. In
patients with DCM without conduction defects, current
guidelines propose genetic testing in the presence of a
family history of cardiomyopathy or a relative with
sudden unexplained death before age 35, indicating a
genetic etiology [16]. However, the decision of when to
start prophylactic treatment is still a challenge.
Genetic testing should be considered in ARVC patients
[17]. Relatives carrying the family mutation have
increased risk of arrhythmias and should be examined
with electrocardiogram, Holter recording, exercise test-
ing, imaging, and (if needed) electrophysiologic studies
and biopsies for risk stratification. Onset is rare during
childhood but is common during adolescence [17].
A recommendation of avoiding long-time endurance
sports may be indicated as such athletes appear to have
more severe forms of the disease [15].
Table 1. Specific cardiomyopathies and genes available for screening in a clinical setting
Disease Genes
Arrhythmogenic right ventricular cardiomyopathy PKP2, DSP, DSG2, DSC2, JUP
Hypertrophic cardiomyopathy MYH7, MYL3, MYL2, ACTC, TNNT2, TPM1, TNNI3, MYBPC3, TTN
Dilated cardiomyopathy LMNA, MYH7, TNNT2, TPM1, TNNI3
Long QT syndrome KCNQ1, HERG, SCN5A, KCNE1, KCNE2, KCNJ2
Short QT syndrome KCNQ1, HERG, KCNJ2
Catecholaminergic polymorphic ventricular tachycardia RyR2, CASQ2
Brugada syndrome SCN5A, CACNA1C, CACNB2b, CACNA2D1
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pathies is specific to each disease. Genotyping should be
performed when a clinical phenotype is present and may
confirm diagnosis and provide added value in risk
stratification. The management of each patient is based
on clinical criteria. Family genetic screening identifies
mutation carriers among relatives, and preventive treat-
ment can be provided in high-risk individuals.
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